Drug intelligence / Profile preview

ADVC007

Development stage: Preclinical
Lead developer: Advancell
Modality: Small Molecules

Overview

ADVC007 is a chemical drug under preclinical development by AdvanCell Isotopes for the treatment of neoplasms, specifically breast cancer and lung cancer. It is also being investigated for potential use in respiratory diseases as well as skin and musculoskeletal diseases. The precise mechanism of action, molecular target, and detailed pharmacological profile have not been disclosed publicly. The drug has not yet entered clinical trials or received regulatory approval[1][2].

Beyond the preview

Go deeper on ADVC007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADVC007.

Explore the full profile